Literature DB >> 20436781

Measurement of antiretroviral drugs in the lungs of HIV-infected patients.

Homer L Twigg1, Carol T Schnizlein-Bick, Michael Weiden, Fred Valentine, Joseph Wheat, Richard B Day, Helen Rominger, Lu Zheng, Ronald G Collman, Robert W Coombs, R Pat Bucy, Naser L Rezk, Angela Dm Kashuba.   

Abstract

AIMS: Prior studies have shown that HAART is associated with decreased HIV viral load in the lungs. The correlation between antiretroviral exposure in bronchoalveolar lavage (BAL) fluid and virologic response was evaluated in patients starting HAART and enrolled in The AIDS Clinical Trial Group Protocol 723. MATERIALS #ENTITYSTARTX00026;
METHODS: A total of 24 subjects underwent blood and BAL sampling prior to starting HAART, and after 4 and 24 weeks of HAART. Drug concentrations and HIV RNA were measured in paired plasma and BAL samples.
RESULTS: Antiretroviral drugs, including efavirenz, were detectable in BAL fluid of HIV-infected subjects beginning HAART. Efavirenz was also associated with a higher likelihood of clearing HIV RNA from the lungs.
CONCLUSION: These results suggest the excellent pulmonary virologic response to antiretroviral therapy may, in part, be due to penetration of antiretroviral drugs into the alveolar compartment.

Entities:  

Year:  2010        PMID: 20436781      PMCID: PMC2861507          DOI: 10.2217/hiv.10.5

Source DB:  PubMed          Journal:  HIV Ther        ISSN: 1758-4329


  14 in total

1.  Simultaneous determination of six HIV nucleoside analogue reverse transcriptase inhibitors and nevirapine by liquid chromatography with ultraviolet absorbance detection.

Authors:  Naser L Rezk; Richard R Tidwell; Angela D M Kashuba
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2003-07-05       Impact factor: 3.205

Review 2.  The antimicrobial therapy puzzle: could pharmacokinetic-pharmacodynamic relationships be helpful in addressing the issue of appropriate pneumonia treatment in critically ill patients?

Authors:  Federico Pea; Pierluigi Viale
Journal:  Clin Infect Dis       Date:  2006-05-10       Impact factor: 9.079

Review 3.  Management of advanced HIV disease: resistance, antiretroviral brain penetration and malignancies.

Authors:  M Boffito; D Pillay; E Wilkins
Journal:  Int J Clin Pract       Date:  2006-09       Impact factor: 2.503

4.  Viral suppression and immune restoration in the gastrointestinal mucosa of human immunodeficiency virus type 1-infected patients initiating therapy during primary or chronic infection.

Authors:  Moraima Guadalupe; Sumathi Sankaran; Michael D George; Elizabeth Reay; David Verhoeven; Barbara L Shacklett; Jason Flamm; Jacob Wegelin; Thomas Prindiville; Satya Dandekar
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

Review 5.  Pulmonary infectious complications of human immunodeficiency virus infection. Part I.

Authors:  J F Murray; J Mills
Journal:  Am Rev Respir Dis       Date:  1990-05

Review 6.  Pulmonary infectious complications of human immunodeficiency virus infection. Part II.

Authors:  J F Murray; J Mills
Journal:  Am Rev Respir Dis       Date:  1990-06

7.  Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution.

Authors:  S I Rennard; G Basset; D Lecossier; K M O'Donnell; P Pinkston; P G Martin; R G Crystal
Journal:  J Appl Physiol (1985)       Date:  1986-02

8.  Pulmonary manifestations of HIV infection in the era of highly active antiretroviral therapy.

Authors:  A J Wolff; A E O'Donnell
Journal:  Chest       Date:  2001-12       Impact factor: 9.410

9.  Effect of highly active antiretroviral therapy on viral burden in the lungs of HIV-infected subjects.

Authors:  Homer L Twigg Iii; Michael Weiden; Fred Valentine; Carol T Schnizlein-Bick; Roland Bassett; Lu Zheng; Joseph Wheat; Richard B Day; Helen Rominger; Ronald G Collman; Lawrence Fox; Barbara Brizz; Joan Dragavon; Robert W Coombs; R Pat Bucy
Journal:  J Infect Dis       Date:  2008-01-01       Impact factor: 5.226

Review 10.  Impact of highly active antiretroviral therapy on organ-specific manifestations of HIV-1 infection.

Authors:  D Torre; F Speranza; R Martegani
Journal:  HIV Med       Date:  2005-03       Impact factor: 3.180

View more
  10 in total

Review 1.  HIV-associated lung infections and complications in the era of combination antiretroviral therapy.

Authors:  Kristina Crothers; Bruce W Thompson; Kathryn Burkhardt; Alison Morris; Sonia C Flores; Philip T Diaz; Richard E Chaisson; Gregory D Kirk; William N Rom; Laurence Huang
Journal:  Proc Am Thorac Soc       Date:  2011-06

2.  Highly active antiretroviral therapy reduces pulmonary IL-8 in HIV-positive women smokers.

Authors:  Gregory H Taylor; Adrienne A Williams; Alfredo Garzino-Demo
Journal:  Pathog Dis       Date:  2015-12-09       Impact factor: 3.166

3.  Towards COVID-19 Prophylaxis: An AIDS Preclinical Research Perspective.

Authors:  Michele Di Mascio
Journal:  Cancer Stud Ther       Date:  2020-07-19

4.  Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy : A Cohort Study.

Authors:  Julia Del Amo; Rosa Polo; Santiago Moreno; Asunción Díaz; Esteban Martínez; José Ramón Arribas; Inma Jarrín; Miguel A Hernán
Journal:  Ann Intern Med       Date:  2020-06-26       Impact factor: 25.391

5.  HIV-1 Transcription Inhibitor 1E7-03 Restores LPS-Induced Alteration of Lung Leukocytes' Infiltration Dynamics and Resolves Inflammation in HIV Transgenic Mice.

Authors:  Marina Jerebtsova; Asrar Ahmad; Xiaomei Niu; Ornela Rutagarama; Sergei Nekhai
Journal:  Viruses       Date:  2020-02-12       Impact factor: 5.048

6.  Potential anti-COVID-19 agents, cepharanthine and nelfinavir, and their usage for combination treatment.

Authors:  Hirofumi Ohashi; Koichi Watashi; Wakana Saso; Kaho Shionoya; Shoya Iwanami; Takatsugu Hirokawa; Tsuyoshi Shirai; Shigehiko Kanaya; Yusuke Ito; Kwang Su Kim; Takao Nomura; Tateki Suzuki; Kazane Nishioka; Shuji Ando; Keisuke Ejima; Yoshiki Koizumi; Tomohiro Tanaka; Shin Aoki; Kouji Kuramochi; Tadaki Suzuki; Takao Hashiguchi; Katsumi Maenaka; Tetsuro Matano; Masamichi Muramatsu; Masayuki Saijo; Kazuyuki Aihara; Shingo Iwami; Makoto Takeda; Jane A McKeating; Takaji Wakita
Journal:  iScience       Date:  2021-03-26

7.  Impaired differentiation of small airway basal stem/progenitor cells in people living with HIV.

Authors:  Nancy P Y Chung; K M Faisal Khan; Mirko Andreoli; Robert J Kaner; Sarah L O'Beirne; Ronald G Crystal
Journal:  Sci Rep       Date:  2022-02-22       Impact factor: 4.379

8.  Daily tenofovir disoproxil fumarate/emtricitabine and hydroxychloroquine for pre-exposure prophylaxis of COVID-19: a double-blind placebo-controlled randomized trial in healthcare workers.

Authors:  Rosa Polo; Xabier García-Albéniz; Carolina Terán; Miguel Morales; David Rial-Crestelo; M Angeles Garcinuño; Miguel García Del Toro; César Hita; Juan Luis Gómez-Sirvent; Luis Buzón; Alberto Díaz de Santiago; Jose Pérez Arellano; Jesus Sanz; Pablo Bachiller; Elisa Martínez Alfaro; Vicente Díaz-Brito; Mar Masiá; Alicia Hernández-Torres; Jose M Guerra; Jesús Santos; Piedad Arazo; Leopoldo Muñoz; Jose Ramon Arribas; Pablo Martínez de Salazar; Santiago Moreno; Miguel A Hernán; Julia Del Amo
Journal:  Clin Microbiol Infect       Date:  2022-08-05       Impact factor: 13.310

Review 9.  Pulmonary Immune Dysregulation and Viral Persistence During HIV Infection.

Authors:  Yulia Alexandrova; Cecilia T Costiniuk; Mohammad-Ali Jenabian
Journal:  Front Immunol       Date:  2022-01-04       Impact factor: 7.561

10.  Physiologically-Based Pharmacokinetic Modeling to Predict the Clinical Efficacy of the Coadministration of Lopinavir and Ritonavir against SARS-CoV-2.

Authors:  Aarzoo Thakur; Shawn Pei Feng Tan; James Chun Yip Chan
Journal:  Clin Pharmacol Ther       Date:  2020-10-06       Impact factor: 6.903

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.